Novavax Reports its COVID Vaccine is 90 Percent Effective
U.S.-based biotech company Novavax announced Monday that Phase 3 clinical trials of its COVID-19 vaccine show it to be more than 90 percent effective at preventing the disease and provide good protection against variants. A release from the company said the study enrolled 29,960 participants across 119 sites in the United States and Mexico with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease. While demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical as many developing nations are just getting vaccine programs going or have yet to start. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies…